Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05528263 · ClinicalTrials.gov registry record · NA
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 89
- Enrollment target
NCT05528263 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 89 participants.
The verdict
NCT05528263, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
Study Summary
This research is being done to determine whether acupuncture can help prevent or lessen chemotherapy-induced peripheral neuropathy (CIPN), a side effect of some kinds of chemotherapy that causes pain, numbness, tingling, swelling, or muscle weakness mostly in the hands or feet. This research will also help determine whether acupuncture can improve quality of life in patients receiving taxane-based chemotherapy for the treatment of breast cancer. The names of the study activities involved in this study are/is: * Acupuncture treatments for participants in the Acupuncture Group * Nature videos with a relaxation exercise for participants in the Relaxation/ Exercise Group The Comprehensive and Integrative Medicine Institute (CIMI) of South Korea is supporting this research study by providing funding.
Interventions
- DEVICE Acupuncture
- OTHER Nature scenery with a relaxation exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05528263
The ClinicalTrials.gov registry entry for NCT05528263 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acupuncture is the first listed.
NCT05528263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05528263 about?
NCT05528263 is a clinical study titled "Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)". This research is being done to determine whether acupuncture can help prevent or lessen chemotherapy-induced peripheral neuropathy (CIPN), a side effect of some kinds of chemotherapy that causes pain, numbness, tingling, swelling, or muscle weakness mostly in the hands or feet. This research will a...
What is the current status of trial NCT05528263?
This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2022-09-08. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05528263?
The interventions under investigation include: Acupuncture (DEVICE), Nature scenery with a relaxation exercise (OTHER).
Who is sponsoring clinical trial NCT05528263?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.